The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.
Vicky Makker
No relevant relationships to disclose
Fernando O. Recio
No relevant relationships to disclose
Ling Ma
No relevant relationships to disclose
Ursula Matulonis
No relevant relationships to disclose
Jennifer O'Hara Lauchle
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Hema Parmar
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Houston Gilbert
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Yulei Wang
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Hartmut Koeppen
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Jill M Spoerke
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Mark Lackner
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Carol Aghajanian
No relevant relationships to disclose